CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

iron sucrose

Trade name: venofer

Small moleculeexperimental

Intravenous iron sucrose is a commonly used treatment for iron deficiency anemia. Iron sucrose replaces iron in the blood to foster red blood cell production in patients with chronic kidney disease. Iron sucrose has the trade name Venofer. — Wikipedia

Clinical trial activity

34 trials · 37 clinical orgs · 2 marketing orgs

Phase 1
6
Phase 2
11
Phase 3
6
Phase 4
10

Earliest trial started Sep 1, 2002 (NCT03317210)

Timeline

1950s

  1. Feb 1, 1950

    Vifor Inc. — IND Organization

  2. Feb 1, 1950

    Vifor Inc. — IND Organization

2000s

  1. Nov 6, 2000

    Lutipold — First NDA Organization

  2. Nov 6, 2000

    Lutipold — NDA Organization

2010s

  1. Jan 1, 2017

    Vifor Inc. — Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • IronSupplementation

    Iron supplementation

Chemistry & pharmacology

Mol. weight
398.14 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • trivalent saccharose hydroxide ferrous
  • venofer

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07197905Phase 2Oct 31, 2025Dysautonomia International, Vanderbilt University
NCT06994065N/AJun 2, 2025Jinnah Sindh Medical University
NCT07115121N/AFeb 2, 2025RESnTEC, Institute of Research
NCT06487299Phase 2Jul 25, 2024Nanjing Medical University
NCT06911034Phase 4Feb 1, 2024CMH Multan Institute of Medical Sciences
NCT06021457Phase 3Oct 17, 2023Renibus Therapeutics, Inc.
NCT05921968Phase 4Jul 30, 2023Ain Shams University
NCT06703411Phase 4May 1, 2023Cheng-Hsin General Hospital
NCT06596161N/AFeb 25, 2023Central Park Medical College
NCT05353348N/ASep 1, 2022Zhejiang University
NCT05456932Phase 4Aug 19, 2022Leiden University, Maastricht University, Radboud University, University of Groningen
NCT05251493Phase 3Jun 6, 2022Government of Canada, Saskatchewan Centre for Patient-Oriented Research
NCT06556134Phase 4Jul 1, 2021Centre Hospitalier Hassan II - Fès
NCT05734716Phase 4Feb 17, 2021University of Oregon
NCT04564833Phase 2Nov 23, 2020Renibus Therapeutics, Inc.
NCT04464850Phase 3Jul 29, 2020Chiangmai University
NCT04491916N/AApr 1, 2020Kaohsiung Medical University
NCT04155814Phase 1Oct 15, 2019Baxalta, Quotient
NCT03893799Phase 1Aug 15, 2019Renibus Therapeutics, Inc.
NCT03933813Phase 1/Phase 2 (Phase 2)Jul 15, 2019University of Wisconsin
Showing 20 of 34 trials
Page 1 / 2

Organizations

Research & Development (37)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Renibus Therapeutics, Inc.For profit5532018
AMAG Pharmaceuticals, Inc.For profit2212018
Jiao Tong UniversityAcademic/Hospital2212015
Zhejiang UniversityAcademic/Hospital2122017
Ain Shams UniversityAcademic/Hospital1112023
Assiut UniversityAcademic/Hospital111—
BaxaltaFor profit1112019
Central Park Medical CollegeAcademic/Hospital1112023
Centre Hospitalier Hassan II - FèsAcademic/Hospital1112021
Cheng-Hsin General HospitalAcademic/Hospital1112023
Chiangmai UniversityAcademic/Hospital1112020
CMH Multan Institute of Medical SciencesAcademic/Hospital1112024
Dysautonomia InternationalAcademic/Hospital1012025
Federal Teaching Hospital AbakalikiAcademic/Hospital1112018
Fundación Canaria Rafael Clavijo para la Investigación BiomédicaAcademic/Hospital1112007
Government of CanadaGovernment1112022
Imperial College LondonAcademic/Hospital1112015
Jinnah Sindh Medical UniversityAcademic/Hospital1112025
Kaohsiung Medical UniversityAcademic/Hospital1112020
Leiden UniversityAcademic/Hospital1112022
37 organizations
Page 1 / 2

Marketing (2)

OrganizationOrg typeRelationshipDate
LutipoldFor profitNDANov 6, 2000
Vifor Inc.For profitINDFeb 1, 1950